International network for comparison of HIV neutralization assays: The neutnet report II

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Heyndrickx, Leo ^e   Heath, Alan ^d   Sheik Khalil, Enas ^c   Alcami, Jose ^a   Bongertz, Vera ^b   Jansson, Marianne ^f   Malnati, Mauro ^g   Montefiori, David ^h   Moog, Christiane ⁱ   Morris, Lynn ^j   Osmanov, Saladin ^k   Polonis, Victoria ^l   Ramaswamy, Meghna ^d   Sattentau, Quentin ^m   Tolazzi, Monica ^g   Schuitemaker, Hanneke ⁿ   Willems, Betty ^e   Wrin, Terri ^o   Fenyö, Eva Maria ^c   Scarlatti, Gabriella ^g  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c LUND UNIVERSITY   (Sweden)

^d NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^e INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^f KAROLINSKA INSTITUTE   (Sweden)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITÉ DE STRASBOURG   (France)

^j NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

^l HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ ACADEMIC MEDICAL CENTER   (Netherlands)

^o MONOGRAM BIOSCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; BETA GALACTOSIDASE; CD4 ANTIGEN; GLYCOPROTEIN GP 160; GREEN FLUORESCENT PROTEIN; LUCIFERASE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CELL LINE; CELL STRAIN HEK293; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERMETHOD COMPARISON; LABORATORY TEST; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PSEUDOTYPING; QUANTITATIVE ANALYSIS; REPORTER GENE; SENSITIVITY ANALYSIS; VIRUS GENE; VIRUS NEUTRALIZATION; VIRUS VIRULENCE; BIOASSAY; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; HELA CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; SENSITIVITY AND SPECIFICITY; STANDARD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; FEMALE; HELA CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; SENSITIVITY AND SPECIFICITY;

EID: 84860727717     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036438     Document Type: Article

References (43)

1. Belshe RB, Graham BS, Keefer MC, Gorse GJ, Wright P, et al. (1994) Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network. JAMA: the journal of the American Medical Association 272: 475-480.
2. Esparza J, Osmanov S, (2003) HIV vaccines: a global perspective. Current molecular medicine 3: 183-193.
3. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, et al. (1988) Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proceedings of the National Academy of Sciences of the United States of America 85: 4478-4482.
4. McElrath MJ, Corey L, Montefiori D, Wolff M, Schwartz D, et al. (2000) A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS research and human retroviruses 16: 907-919.
5. Fenyo EM, Albert J, McKeating J, (1996) The role of the humoral immune response in HIV infection. AIDS 10 Suppl A pp. S97-106.
6. Osmanov S, Heyward WL, Esparza J, (1994) The World Health Organization Network for HIV Isolation and Characterization: summary of a pilot study. AIDS research and human retroviruses 10: 1325-1326.
7. McCarthy M, (2003) HIV vaccine fails in phase 3 trial. Lancet 361: 755-756.
8. (2007) HIV vaccine failure prompts Merck to halt trial. Nature 449: 390.
9. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF, (2010) The immune response during acute HIV-1 infection: clues for vaccine development. Nature reviews Immunology 10: 11-23.
10. Moore JP, Cao Y, Leu J, Qin L, Korber B, et al. (1996) Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of virology 70: 427-444.
11. Nyambi PN, Nkengasong J, Lewi P, Andries K, Janssens W, et al. (1996) Multivariate analysis of human immunodeficiency virus type 1 neutralization data. Journal of virology 70: 6235-6243.
12. Weber J, Fenyo EM, Beddows S, Kaleebu P, Bjorndal A, (1996) Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. Journal of virology 70: 7827-7832.
13. D'Souza MP, Durda P, Hanson CV, Milman G, (1991) Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. AIDS 5: 1061-1070.
14. D'Souza MP, Livnat D, Bradac JA, Bridges SH, (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. The Journal of infectious diseases 175: 1056-1062.
15. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. Journal of virology 79: 10108-10125.
16. Todd CA, Greene KM, Yu X, Ozaki DA, Gao H, et al. (2011) Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells. Journal of immunological methods.
17. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: the NeutNet report. PloS one 4: e4505.
18. Davis D, Donners H, Willems B, Vermoesen T, Heyndrickx L, et al. (2003) Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases. Journal of medical virology 71: 332-342.
19. Quakkelaar ED, van Alphen FP, Boeser-Nunnink BD, van Nuenen AC, Pantophlet R, et al. (2007) Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies. Journal of virology 81: 8533-8542.
20. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, et al. (1993) Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. The Journal of infectious diseases 168: 207-210.
21. Holl V, Peressin M, Decoville T, Schmidt S, Zolla-Pazner S, et al. (2006) Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. Journal of virology 80: 6177-6181.
22. Polonis VR, De Souza MS, Chanbancherd P, Chantakulkij S, Jugsudee A, et al. (2001) HIV type 1 subtype E-infected patients with broadened, dual (B/E) V3 loop serology have increased cross-neutralizing antibodies. AIDS research and human retroviruses 17: 69-79.
23. Nordqvist A, Fenyo EM, (2005) Plaque-reduction assays for human and simian immunodeficiency virus neutralization. Methods in molecular biology 304: 273-285.
24. Shi Y, Albert J, Francis G, Holmes H, Fenyo EM, (2002) A new cell line-based neutralization assay for primary HIV type 1 isolates. AIDS research and human retroviruses 18: 957-967.
25. Morner A, Bjorndal A, Albert J, Kewalramani VN, Littman DR, et al. (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. Journal of virology 73: 2343-2349.
26. Maddon PJ, Dalgleish AG, McDougal JS, Clapham PR, Weiss RA, et al. (1986) The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 47: 333-348.
27. Montefiori DC, (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
28. Richman DD, Wrin T, Little SJ, Petropoulos CJ, (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 100: 4144-4149.
29. Heyndrickx L, Vermoesen T, Vereecken K, Kurth J, Coppens S, et al. (2008) Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. J Virol Methods 148: 166-173.
30. Garcia-Perez J, Perez-Olmeda M, Sanchez-Palomino S, Perez-Romero P, Alcami J, (2008) A new strategy based on recombinant viruses for assessing the replication capacity of HIV-1. HIV medicine 9: 160-171.
31. Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, et al. (2010) A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. Journal of Antimicrobial Chemotherapy 65: 2493-2501.
32. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, et al. (2006) CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome biology 7: R100.
33. Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, et al. (1998) Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. Journal of virology 72: 6988-6996.
34. Lauren A, Thorstensson R, Fenyo EM, (2006) Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): the kinetics of evolution to neutralization resistance are related to progression rate of disease. The Journal of general virology 87: 595-606.
35. Ozkaya Sahin G, Bowles EJ, Parker J, Uchtenhagen H, Sheik-Khalil E, et al. (2010) Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS pathogens 6: e1001084.
36. Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, et al. (2012) Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. Journal of virology 86: 961-971.
37. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS pathogens 6: e1001028.
38. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, et al. (2009) Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. Journal of virology 83: 1045-1059.
39. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, et al. (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 83: 8925-8937.
40. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320.
41. von Bubnoff A, (2010) Antibodies: beyond neutralization. IAVI report: newsletter on international AIDS vaccine research 14: 8-12.
42. Forthal DN, Moog C, (2009) Fc receptor-mediated antiviral antibodies. Current opinion in HIV and AIDS 4: 388-393.
43. Ljunggren K, Bottiger B, Biberfeld G, Karlson A, Fenyo EM, et al. (1987) Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. Journal of immunology 139: 2263-2267.